Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-09-19 / Cancers (Basel) 2019 Sep;11(9)Past, Current, and Future of Immunotherapies for Prostate Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2019-09-11 / Front Oncol 2019;9:884Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-08-14 / Front Immunol 2019;10:1939Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-04-29 / Int. J. Cancer 2019 10;145(7):1958-1969On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-02-06 / Front Oncol 2019;9:50Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2019-01-01 / Klin Onkol 2019;32(1):70-74Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-12-05 / Front Immunol 2018;9:2759
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de